Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiangchen Han
Observed names:
X Han,
X. Han,
XIANGCHEN HAN,
Xiang‐Chen Han
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shandong Tumor Hospital,
Nanjing Medical University
ORCID:
0000-0001-7894-7024
Observed ORCID:
0000-0001-7894-7024
OpenAlex ID:
A5100634182
The BCL2 major breakpoint region (mbr) regulates gene expression
2006
·
C Ma
, J Zhang
, et al.
·
Oncogene
·
34
Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4
2025
·
Zhangyuan Gu
, Fugui Ye
, et al.
·
Journal of Biomedical Science
·
20
Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer
2024
·
Wenxiao Yang
, Luo Hong
, et al.
·
Cell Discovery
·
18
Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer
2021
·
Lin‐Wei Guo
, Xiao‐Guang Li
, et al.
·
Clinical and Translational Medicine
·
17
Integrated Multi-Omics Profiling of Young Breast Cancer Patients Reveals a Correlation between Galactose Metabolism Pathway and Poor Disease-Free Survival
2023
·
XIANGCHEN HAN
, BOYUE HAN
, et al.
·
Cancers
·
11
PDF
Multiomics and single‐cell sequencings reveal the specific biological characteristics of low Ki‐67 triple‐negative breast cancer
2024
·
Boyue Han
, Xiangchen Han
, et al.
·
Cancer Innovation
·
3
PDF
14P Circulating tumor DNA (ctDNA) residual and dynamics of ctDNA clonality indicated therapeutic efficacy of sintilimab plus docetaxel in previously treated advanced non-small cell lung cancer
2021
·
Z. Wang
, X. Han
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
7
Citation count:
103
H-index:
5
I10-index:
5
Year
Topic
Type